Neuropsychiatric symptoms and interleukin-6 serum levels in acute stroke

Gianfranco Spalletta, Luca Cravello, Francesca Imperiale, Francesca Salani, Paola Bossù, Livio Picchetto, Marina Cao, Maurizia Rasura, Floriana Pazzelli, Francesco Orzi, Carlo Caltagirone, Robert G. Robinson, Claudia Cacciari

Research output: Contribution to journalArticlepeer-review


The role of interleukin-6 (IL-6) as a risk factor for developing depressive symptoms, neuropsychological impairment, and related functional and neurological symptom severity during the acute phase of ischemic stroke is still underexplored. Here, the authors assessed this issue, in 48 patients without significant clinical history for major medical illnesses or other factors that promote inflammation, 72 hours after a first-ever acute ischemic stroke. In the acute phase of ischemic stroke, increased IL-6 plays a key role in the onset of depressive disorders, apathy/amotivation, somatic symptoms of depression, and neurological/functional symptoms, resulting in higher disability and poor outcome of stroke patients.

Original languageEnglish
Pages (from-to)255-263
Number of pages9
JournalJournal of Neuropsychiatry and Clinical Neurosciences
Issue number4
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology


Dive into the research topics of 'Neuropsychiatric symptoms and interleukin-6 serum levels in acute stroke'. Together they form a unique fingerprint.

Cite this